Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04123418 · ClinicalTrials.gov registry record · Phase 1
A Study of WVT078 in Patients With Multiple Myeloma (MM)
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT04123418 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT04123418, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)
Interventions
- BIOLOGICAL WVT078
- DRUG WHG626
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-12-05 |
| Est. Completion | 2024-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04123418
The ClinicalTrials.gov registry entry for NCT04123418 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which WVT078 is the first listed.
NCT04123418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04123418 about?
NCT04123418 is a clinical study titled "A Study of WVT078 in Patients With Multiple Myeloma (MM)". The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)
What is the current status of trial NCT04123418?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-12-05. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT04123418?
The interventions under investigation include: WVT078 (BIOLOGICAL), WHG626 (DRUG).
Who is sponsoring clinical trial NCT04123418?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.